Načítá se...
Making the Right Choice: Optimizing rt-PA and eptifibatide lysis, an in vitro study
INTRODUCTION: Recombinant tissue plasminogen activator (rt-PA) is the only FDA approved lytic therapy for acute ischemic stroke. However, there can be complications such as intra-cerebral hemorrhage. This has led to interest in adjuncts such as GP IIb-IIIa inhibitors. However, there is little data o...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2010
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2946496/ https://ncbi.nlm.nih.gov/pubmed/20813398 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.thromres.2010.07.020 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|